MABSol® Biotinylated Human Her2, His Tag, primary amine labeling, long spacer (HE2-H822R) is expressed from human HEK293 cells. It contains AA Thr 23 - Thr 652 (Accession # P04626-1). It is the biotinylated form of Human Her2, His Tag (Cat. No. HE2-H5225).
Predicted N-terminus: Thr 23
Request for sequence
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 70.2 kDa. The protein migrates as 85-100 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with biotins using standard chemical labeling method. A specially optimized long-spacer biotin reagent (32.5 angstroms) is used in this product to minimize potential steric hindrance.
Passed as determined by the HABA assay / binding ELISA.
Less than 1.0 EU per μg by the LAL method.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 24 months in lyophilized state;
- -70°C for 12 months under sterile conditions after reconstitution.
Biotinylated Human Her2, His Tag, primary amine labeling, long spacer on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized Trastuzumab at 3 μg/mL (100 μL/well) can bind Biotinylated Human Her2, His Tag, primary amine labeling, long spacer (Cat. No. HE2-H822R) with a linear range of 0.1-3.1 ng/mL (QC tested).
Immobilized Herceptin on SA Biosensor via Biotinylated Human Her2, His Tag, primary amine labeling, long spacer (Cat. No. HE2-H822R), can bind Human FCGRT&B2M Heterodimer Protein, His Tag&Strep II Tag (SPR & BLI verified) (Cat. No. FCM-H5286) with an affinity constant of 1.32 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
2e5 of Anti-Her2 CAR-293 cells were stained with 100 μL of 1μg/mL of Biotinylated Human Her2, His Tag, primary amine labeling, long spacer (Cat. No. HE2-H822R) and negative control protein respectively, washed and then followed by PE-SA and analyzed with FACS (Routinely tested).
The Impact of FcγRI Binding on ImmunoPET
Authors: Vivier D, et al
Journal: J NUCL MED 2019
Small-molecule probes for affinity-guided introduction of biocom-patible handles on metal-binding proteins
Authors: Mortensen MR, et al.
Journal: Bioconjug Chem 2018
Antibody-drug conjugate having improved stability and use thereof
Authors: Kim Young Min, et al.
Journal: US20160136300A1 2016
Human Epidermal growth factor Receptor 2 (HER2) is also called ERBB2, HER-2,HER-2 /neu, NEU, NGL,TKR1 and c-erb B2,and is a protein giving higher aggressiveness in breast cancers. It is a member of the ErbB protein family, more commonly known as the epidermal growth factor receptor family. HER2 is a cell membrane surface-bound receptor tyrosine kinase and is normally involved in the signal transduction pathways leading to cell growth and differentiation. HER2 is thought to be an orphan receptor, with none of the EGF family of ligands able to activate it. Approximately 30% of breast cancers have an amplification of the HER2 gene or overexpression of its protein product. Overexpression of this receptor in breast cancer is associated with increased disease recurrence and worse prognosis. HER2 appears to play roles in development, cancer, communication at the neuromuscular junction and regulation of cell growth and differentiation .